I can extract side effects.

Chapter 101 Academician's Attack
This time it was Weikang who issued the announcement. He said that the company's new drug research and development has reached a virtuous circle, and there is no shortage of money for the time being.

On the contrary, the next goal is to spend more money, especially R&D investment. Sanqing still has a clear gap with international pharmaceutical giants in this field. The short-term goal is to catch up, and the long-term goal is to strive to far surpass its peers.

At the same time, the pharmaceutical business of Sanqing Group will definitely not be listed.

As soon as the news came out, all the netizens immediately laughed.

"President Wei is awesome, a man who can't get capital."

"I'm really happy to see the capital shrinking."

"The next goal is to spend more money, to equalize Pfizer, right? I laughed out loud."

"It should be like this. Pharmaceutical companies should serve the people and meet social needs. How can they be controlled in the hands of capitalists?"

"If you don't go public, you won't be controlled by capital, and you won't sell high-priced drugs. Now we can rest assured."

"Foreign pharmaceutical giants spend tens of billions of dollars on research and development every year. I think Mr. Wei's spending plan may be a bit difficult."

"It's not difficult, it's not difficult, give each person 100 yuan to the people of the whole country, and it's easy to achieve the goal, hahaha."

"Don't you see Mr. Wei's meaning? This is the rhythm of one person driving a city. Kun City is about to develop, and housing prices are expected to soar!"

"I can see that [-]% of them are going to recruit again. Hey, I'm graduating soon, and I'm going to submit my resume."

"I'm envious of the top student upstairs. If I could go back in time, I would have chosen to major in biochemistry back then."

"Among other things, if Sanqing's R&D investment is as high as Juwei's, it will be able to support the entire domestic pharmaceutical industry."

"Yeah, you don't know that the R&D investment of domestic pharmaceutical companies is not as much as that of a foreign giant, and the R&D investment of foreign pharmaceutical giants is not as good as Juwei, whose R&D investment ranks No. [-] in the world. three."

"Hiss, it's so terrifying. Is Sanqing going to become the domestic R&D double champion with Juwei?"

"Hedong for 30 years, and Hexi for 30 years, Fengshui has taken turns. This year, I will be in the pharmaceutical industry, and my biochemical, environmental, and material cooperation should be prosperous!"

Not to mention the excitement and agitation of netizens, the eagerness of the financial circle, and the bosses of domestic pharmaceutical companies couldn't help but blush when they saw Sanqing's statement, so they turned their heads away one after another, as if they couldn't see it.

"The conditions of the country are so helpless." They thought so.

The inertia of a person is often terribly stubborn, let alone the inertia of an industry.

Although Sanqing is working hard to go against the trend, it is not yet time to reverse the situation in the industry.

Just when people in the industry kept silent about this statement, a post suddenly appeared on the Internet: "From the statement of Sanqing to the R&D investment of my country's pharmaceutical industry, I am amazed!"

The person who posted the post is Chang Sanwei, the dean of the Department of Biology at Peking University, a well-known biological scientist, and an academician of the Academy of Sciences. Often ranting.

The post analyzed the research and development investment of major domestic pharmaceutical companies in detail, and praised Sanqing's emphasis on research and development, which immediately sparked heated discussions across the Internet.

"At this moment, there is a phenomenon that can be called 'Huaxia Surprise' in the domestic pharmaceutical industry."

"The most profitable pharmaceutical company with the largest revenue in the industry does not go public or raise funds, and spends the money it earns silently on drug research and development and basic scientific research. One company supports an industry."

"However, the listed pharmaceutical companies insist on following a path full of Chinese characteristics.

The data shows that the total R&D expenses of 373 listed pharmaceutical companies last year were only 613 billion yuan, which was lost to the multinational pharmaceutical company Roche.

Take Hengrui, a pharmaceutical leader, as an example. Last year, the company’s research and development expenses ranked outside the top 40 global pharmaceutical companies.If all the sales expenses are spent on research and development, the total research and development expenses will be about 19 billion US dollars, and the ranking will be greatly improved to about 20, which can be on an equal footing with mid-level pharmaceutical companies such as Novo Nordisk.

Domestic pharmaceutical companies have made a lot of money in the past two years. Where did they spend their money?
The answer is marketing promotion.

Last year, a total of 373 listed companies released their performance reports, with a total revenue of 1.92 trillion yuan and a net profit of 1351 billion yuan.Sales expenses are as high as 2790 billion yuan, of which 672 billion yuan is sales staff salaries, and the remaining 2118 billion yuan is mainly used for promotion, including academic promotion, entertainment expenses, conference fees, publicity expenses, travel expenses, etc.

Take Hengrui Medicine as an example. Last year, the company had a total revenue of 277 billion yuan and a net profit of 63 billion yuan.The annual sales cost is 98 billion yuan, of which 42 billion yuan is used in academic promotion, innovative drug professional platform construction and other marketing expenses.

One investment and one harvest, the investment is so low, the whole industry is naturally full of bubbles.Although the PPTs of various innovative drug companies boast hype, in fact 90% of domestic new drug projects are derivative new drugs developed for targets that have been verified at home and abroad.

Although derivative drugs imitate the original drug, but slightly change the chemical structure of the original drug, strictly speaking, they are all derivative drugs.

Foreign new drugs are all original research new drugs, which are the first or best in their class. The cost of new drug development is 10 billion to 22 billion US dollars. The success rate from entering the clinic to obtaining the new drug approval is 9.6%, while the development cost of domestic derived new drugs is less than 1 million. In US dollars, the success rate from clinical practice to obtaining new drug approval is as high as 80%.

This copycat-style new drug strategy looks beautiful, but it also means reduced profit prospects and intensified business competition.

So, is there any bright spot in my country's pharmaceutical industry that can lead the world?

This, of course.

That is - the valuation is absolutely the highest in the world.

From the perspective of market size, the current scale of my country's pharmaceutical market is about 8000 billion yuan, about 4 times that of my country, and the world's pharmaceutical market has reached 1.2 trillion US dollars, about 9 times that of my country.

From the perspective of corporate strength, those foreign pharmaceutical companies that have the latest and best real new drug products of the same category have high R&D investment and high income and profits, but their market value is lower than that of a domestic pharmaceutical company that only has derivative products in the domestic market.

Doesn't this make people feel funny and ridiculous?

Isn't this a surprise for Huaxia?

Hehe, it can be said that the current domestic new drug companies are focused on selling cabbage, and they are valued at selling.bai.fen.

In any case, to forge iron requires hard work. If you want to produce results, you need not only hard power, but also real money in scientific research.

This industry needs to be like Sanqing, calm down and cultivate internal strength, so as to keep up with the pace of the leader, not to fall behind, not to fall behind.Otherwise, I am afraid that there will be a brutal cleansing and reshuffle. After the market competition is over, there will be a lot of chicken feathers. How many companies will be able to stand up. "

Netizens exclaimed and sighed after watching it.

"Sanqing is indeed a clean stream in the industry."

"This is definitely an insider who sees clearly. The reform of this industry is imperative."

"To be honest, I would rather only have Sanqing as one company in the entire industry, and I don't want to spend money on medicines from these waste pharmaceutical companies."

"So that's it. I finally understand how all kinds of strange phenomena in the pharmaceutical industry come about."

"It's no wonder that the price of medicines is getting higher and higher, but the medicines that are really effective still have to be imported. It turns out that they are all used by these grandchildren for marketing."

"Oh my god, I'm an academician, I'm afraid I'm going to offend a lot of people now."

"Everyone is an academician, what's so scary, our country needs such experts to speak out, so as to urge the industry to move forward."

"This is the real expert. It's really good. I love it."

"I hope that Sanqing can play a leading role in the industry, even if it can make other pharmaceutical companies follow suit."

"I don't think so. If you earn a lot of quick money, can you still earn the slow and difficult hard money for research and development?"

This proclamation also reached Wei Kang's ears. He watched it carefully and sighed: "The one who knows me is Mo Ruojun."

This post simply spoke to his heart, and the other party also praised Sanqing greatly.

That must show support.

Wei Kang acted quickly, and immediately contacted Academician Chang through Academician Qi, and invited him to become an honorary advisor of Sanqing.

The two sides hit it off immediately, and Sanqing took advantage of the opportunity to propose a strategic cooperation between the school and the enterprise with the Department of Biology and Chemistry of Peking University.

Now that Sanqing is rich and famous, what it lacks most is cutting-edge scientific research strength and outstanding talents in the industry.

Wei Kang looked at the talents of Peking University and was very envious. In the past, these people had to study abroad, and most of them would not come back.

Now that Sanqing has gained a reputation among global pharmaceutical companies, its attraction to these high-level talents will surely increase dramatically.

After all, who doesn't want to return home after completing their studies, and return to their hometown with a good clothes.

In the past, there were no domestic pharmaceutical companies that were willing to spend money on scientific research, but now, there are Sanqing.

It is believed that there will be a large wave of overseas talents returning.

And Sanqing also wants to build the world's first biochemical research and development base.

(End of this chapter)